vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and Urban Edge Properties (UE). Click either name above to swap in a different company.
Urban Edge Properties is the larger business by last-quarter revenue ($132.6M vs $86.8M, roughly 1.5× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 12.2%). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 11.6%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
Urban Edge Properties is a publicly traded real estate investment trust (REIT) that owns, operates, and develops high-quality retail and mixed-use properties, primarily located in densely populated urban and suburban markets across the United States. Its portfolio covers grocery-anchored shopping centers, lifestyle outlets, and community-focused commercial assets.
IOVA vs UE — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $132.6M |
| Net Profit | — | $22.6M |
| Gross Margin | 67.4% | — |
| Operating Margin | -84.7% | — |
| Net Margin | — | 17.1% |
| Revenue YoY | 17.7% | 12.2% |
| Net Profit YoY | — | -6.7% |
| EPS (diluted) | — | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $132.6M | ||
| Q4 25 | $86.8M | $119.6M | ||
| Q3 25 | $67.5M | $120.1M | ||
| Q2 25 | $60.0M | $114.1M | ||
| Q1 25 | $49.3M | $118.2M | ||
| Q4 24 | $73.7M | $116.4M | ||
| Q3 24 | $58.6M | $112.4M | ||
| Q2 24 | $31.1M | $106.5M |
| Q1 26 | — | $22.6M | ||
| Q4 25 | — | $12.4M | ||
| Q3 25 | $-91.3M | $14.9M | ||
| Q2 25 | $-111.7M | $58.0M | ||
| Q1 25 | $-116.2M | $8.2M | ||
| Q4 24 | — | $30.1M | ||
| Q3 24 | $-83.5M | $9.1M | ||
| Q2 24 | $-97.1M | $30.8M |
| Q1 26 | — | — | ||
| Q4 25 | 67.4% | — | ||
| Q3 25 | 43.0% | — | ||
| Q2 25 | 5.5% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 68.7% | — | ||
| Q3 24 | 46.2% | — | ||
| Q2 24 | -0.8% | — |
| Q1 26 | — | — | ||
| Q4 25 | -84.7% | 11.3% | ||
| Q3 25 | -140.7% | 13.4% | ||
| Q2 25 | -189.8% | 53.9% | ||
| Q1 25 | -245.8% | 7.6% | ||
| Q4 24 | -117.5% | 27.6% | ||
| Q3 24 | -152.1% | 8.9% | ||
| Q2 24 | -327.6% | 30.6% |
| Q1 26 | — | 17.1% | ||
| Q4 25 | — | 10.4% | ||
| Q3 25 | -135.3% | 12.4% | ||
| Q2 25 | -186.2% | 50.8% | ||
| Q1 25 | -235.5% | 6.9% | ||
| Q4 24 | — | 25.9% | ||
| Q3 24 | -142.7% | 8.1% | ||
| Q2 24 | -312.2% | 28.9% |
| Q1 26 | — | $0.18 | ||
| Q4 25 | — | $0.09 | ||
| Q3 25 | — | $0.12 | ||
| Q2 25 | $-0.33 | $0.46 | ||
| Q1 25 | $-0.36 | $0.07 | ||
| Q4 24 | $-0.24 | $0.25 | ||
| Q3 24 | $-0.28 | $0.07 | ||
| Q2 24 | $-0.34 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $50.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $698.6M | $1.4B |
| Total Assets | $913.2M | $3.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $50.0M | ||
| Q4 25 | $297.0M | $48.9M | ||
| Q3 25 | $300.8M | $77.8M | ||
| Q2 25 | $301.2M | $53.0M | ||
| Q1 25 | $359.7M | $48.0M | ||
| Q4 24 | $323.8M | $41.4M | ||
| Q3 24 | $397.5M | $67.9M | ||
| Q2 24 | $412.5M | $78.6M |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $698.6M | $1.4B | ||
| Q3 25 | $702.3M | $1.4B | ||
| Q2 25 | $698.5M | $1.4B | ||
| Q1 25 | $767.9M | $1.4B | ||
| Q4 24 | $710.4M | $1.4B | ||
| Q3 24 | $773.5M | $1.3B | ||
| Q2 24 | $768.5M | $1.3B |
| Q1 26 | — | $3.4B | ||
| Q4 25 | $913.2M | $3.3B | ||
| Q3 25 | $904.9M | $3.3B | ||
| Q2 25 | $907.4M | $3.3B | ||
| Q1 25 | $966.7M | $3.3B | ||
| Q4 24 | $910.4M | $3.3B | ||
| Q3 24 | $991.1M | $3.2B | ||
| Q2 24 | $964.3M | $3.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $39.1M |
| Free Cash FlowOCF − Capex | $-61.9M | — |
| FCF MarginFCF / Revenue | -71.3% | — |
| Capex IntensityCapex / Revenue | 10.7% | 1.5% |
| Cash ConversionOCF / Net Profit | — | 1.73× |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $39.1M | ||
| Q4 25 | $-52.6M | $182.7M | ||
| Q3 25 | $-78.7M | $55.7M | ||
| Q2 25 | $-67.4M | $43.5M | ||
| Q1 25 | $-103.7M | $32.6M | ||
| Q4 24 | $-73.3M | $153.2M | ||
| Q3 24 | $-59.0M | $36.6M | ||
| Q2 24 | $-98.4M | $41.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-61.9M | $81.8M | ||
| Q3 25 | $-89.5M | $26.1M | ||
| Q2 25 | $-74.9M | $19.6M | ||
| Q1 25 | $-109.9M | $11.9M | ||
| Q4 24 | $-77.5M | $42.5M | ||
| Q3 24 | $-61.3M | $12.2M | ||
| Q2 24 | $-98.9M | $19.9M |
| Q1 26 | — | — | ||
| Q4 25 | -71.3% | 68.4% | ||
| Q3 25 | -132.7% | 21.7% | ||
| Q2 25 | -124.9% | 17.2% | ||
| Q1 25 | -222.8% | 10.0% | ||
| Q4 24 | -105.1% | 36.6% | ||
| Q3 24 | -104.6% | 10.8% | ||
| Q2 24 | -317.9% | 18.6% |
| Q1 26 | — | 1.5% | ||
| Q4 25 | 10.7% | 84.4% | ||
| Q3 25 | 16.1% | 24.6% | ||
| Q2 25 | 12.4% | 20.9% | ||
| Q1 25 | 12.6% | 17.5% | ||
| Q4 24 | 5.7% | 95.1% | ||
| Q3 24 | 3.9% | 21.7% | ||
| Q2 24 | 1.4% | 20.1% |
| Q1 26 | — | 1.73× | ||
| Q4 25 | — | 14.71× | ||
| Q3 25 | — | 3.73× | ||
| Q2 25 | — | 0.75× | ||
| Q1 25 | — | 3.97× | ||
| Q4 24 | — | 5.09× | ||
| Q3 24 | — | 4.03× | ||
| Q2 24 | — | 1.34× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
UE
| Rental revenue | $124.2M | 94% |
| Other | $8.4M | 6% |
